GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds
(Barcelona, Spain, Wednesday 8 September 2025) The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.1
GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the United States between 2019 and 2023.² These medications alter glucose metabolism, gastric motility and sympathetic tone, which may lead to unique uptake patterns on PET-CT. Previous case reports have shown increased FDG uptake in skeletal ...